Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 23, pp. 5107-5114
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis
Shitao Jiang, Y. Liu, Han Zheng, et al.
International Journal of Surgery (2023)
Open Access | Times Cited: 88
Immunosurveillance in clinical cancer management
Guido Kroemer, Timothy A. Chan, Alexander M.M. Eggermont, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 74, Iss. 2, pp. 187-202
Open Access | Times Cited: 66
Desmoid Tumors: A Comprehensive Review
Meryem Bektas, Timothy Bell, Shahnaz Khan, et al.
Advances in Therapy (2023) Vol. 40, Iss. 9, pp. 3697-3722
Open Access | Times Cited: 36
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17
Richard Cathomas, Sacha I. Rothschild, Stefanie Hayoz, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 33, pp. 5131-5139
Open Access | Times Cited: 25
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer
Filippo Pederzoli, Michela Riba, Chiara Venegoni, et al.
European Urology (2024) Vol. 85, Iss. 5, pp. 417-421
Open Access | Times Cited: 10
Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma
Joaquim Bellmunt, Brian M. Russell, Bernadett Szabados, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 2
Closed Access | Times Cited: 1
Tracing the Evolution of Sex Hormones and Receptor‐Mediated Immune Microenvironmental Differences in Prostate and Bladder Cancers: From Embryonic Development to Disease
Dengxiong Li, Zhipeng Wang, Qingxin Yu, et al.
Advanced Science (2025)
Open Access | Times Cited: 1
Neoadjuvant Immunotherapy: A Promising New Standard of Care
Emma Boydell, José Luís Sandoval, Olivier Michielin, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11849-11849
Open Access | Times Cited: 17
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer
Roger Li, Luigi Nocera, Kyle Rose, et al.
European Urology Oncology (2024) Vol. 7, Iss. 3, pp. 614-624
Closed Access | Times Cited: 8
Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer
Reuben Ben‐David, Matthew D. Galsky, John P. Sfakianos
Trends in Molecular Medicine (2024) Vol. 30, Iss. 7, pp. 686-697
Closed Access | Times Cited: 8
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors
Alberto Gil-Jimenez, Nick van Dijk, Joris L. Vos, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Lactylation in cancer: Mechanisms in tumour biology and therapeutic potentials
Yipeng He, Tianbao Song, Jinzhuo Ning, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 11
Open Access | Times Cited: 7
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy
Petros Grivas, Vadim S. Koshkin, Xiangying Chu, et al.
European Urology Oncology (2023) Vol. 7, Iss. 4, pp. 914-922
Closed Access | Times Cited: 15
Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer
Mario de Angelis, Giuseppe Basile, Carlo Maria Scornajenghi, et al.
Current Opinion in Urology (2023) Vol. 33, Iss. 5, pp. 354-359
Closed Access | Times Cited: 14
Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
Shibo Huang, Yanping Huang, Chunyan Li, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 6
First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer
Chiara Mercinelli, Marco Moschini, Antonio Cigliola, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 35, pp. 4196-4205
Closed Access | Times Cited: 5
A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder
Roger Li, Wade J. Sexton, Jasreman Dhillon, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 19, pp. 3875-3881
Closed Access | Times Cited: 13
Vesical Imaging‐Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle‐invasive bladder cancer
Andrea Necchi, Giuseppe Basile, Ewan A. Gibb, et al.
BJU International (2023) Vol. 133, Iss. 2, pp. 214-222
Open Access | Times Cited: 13
Immunotherapy‐based neoadjuvant treatment and complication rates after radical cystectomy
Reuben Ben‐David, Francesco Pellegrino, Reza Mehrazin, et al.
BJU International (2025)
Closed Access
New bladder preservation strategies in urothelial carcinoma of the bladder.
Axel Heidenreich, Dirk Böhmer, Christian Bolenz, et al.
Deutsches Ärzteblatt international (2025)
Closed Access
Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High‐Risk Muscle‐Invasive Urothelial Carcinoma: A Real‐World Study
Yanjun Wang, Kaihua Zhong, Xingliang Tan, et al.
Cancer Medicine (2025) Vol. 14, Iss. 4
Open Access
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma
Eric J Miller, Matthew D. Galsky
Expert Review of Anticancer Therapy (2025)
Closed Access
ENPP1 Promotes Immune Suppression, Drug Resistance, and Adverse Outcomes in Bladder Cancer: Potential for Targeted Therapy
Chengyu You, Qixiang Fang, Xi Xiao, et al.
Cancer Genetics (2025) Vol. 294-295, pp. 1-14
Closed Access
The role of the urinary microbiome in genitourinary cancers
Seoho Lee, Karen S. Sfanos, Nirmish Singla
Nature Reviews Urology (2025)
Closed Access
Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study
Nargiz Majıdova, Ahmet Emin Öztürk, Rumeysa Çolak, et al.
Turkish Journal of Clinics and Laboratory (2025) Vol. 16, Iss. 1, pp. 123-130
Open Access
Page 1 - Next Page

Scroll to top